Opinion|Videos|July 23, 2024

Combining In-Office and At-Home Therapies

Author(s)Jessilin Quint, OD, MBA, MS, FAAO, Selina R. McGee, OD, FAAO, Dipl ABO

Dry eye experts provide comprehensive insights on the role of in-office procedural therapies.

Episodes in this series

Selina McGee, OD, FAAO, and Jessilin Quint, OD, MBA, FAAO

EP. 1 Overview of MGD and Its Causes

Selina McGee, OD, FAAO, and Jessilin Quint, OD, MBA, FAAO

EP. 2 Differentiating Aqueous vs Evaporative Dry Eye

Selina McGee, OD, FAAO, and Jessilin Quint, OD, MBA, FAAO

EP. 3 Long-Term Consequences of Untreated MGD

Selina McGee, OD, FAAO, and Jessilin Quint, OD, MBA, FAAO

EP. 4 Factors to Consider in Treatment Selection for MGD

Selina McGee, OD, FAAO, and Jessilin Quint, OD, MBA, FAAO

EP. 5 Managing Evaporative Dry Eye with New FDA-Approved Therapy

Selina McGee, OD, FAAO, and Jessilin Quint, OD, MBA, FAAO

EP. 6 Differentiating Between the Semi-Fluorinated Alkane-Based Therapies for Dry Eye

Jessilin Quint, OD, MBA, FAAO, and Selina McGee, OD, FAAO

EP. 7 Combining In-Office and At-Home Therapies

Jessilin Quint, OD, MBA, FAAO, and Selina McGee, OD, FAAO

EP. 8 Clinical Case Scenario: Management Strategies for MGD and Key Takeaways

Video content above is prompted by the following questions:

When do you reach for procedural therapies for meibomian gland dysfunction (MGD)? What in-office procedural therapies do you use for MGD?

Newsletter

Want more insights like this? Subscribe to Optometry Times and get clinical pearls and practice tips delivered straight to your inbox.

Related Content

Yehia Hashad, MD, executive vice president of research and development and chief medical officer at Bausch + Lomb (Credit: Bausch + Lomb)

Bausch + Lomb advances 2 first-in-class eye health therapies

August 25th 2026

Neel R. Desai, MD (Credit: The Eye Institute of West Florida)

FDA expands TearCare indication to improve meibomian gland function

August 24th 2026

Man at desk holding bridge of nose Image credit: AdobeStock/Prostock-studio

Perceived stress may precede worsening dry eye symptoms in young adults, study finds

ByJordana Joy, Editor

August 21st 2026

Tatiana Noroozian, OD, FAAO

A primer on oral omega-3s and dry eye disease

ByTatiana Noroozian, OD, FAAO

August 20th 2026

Tyrvaya nasal spray Image credit: Viatris

Harrow acquires global rights to Tyrvaya

ByKassi Filkins, Editor

August 7th 2026

Latest CME

(CME Track) Rapid Reviews in Retina™: Emerging Updates from Summer 2025—Addressing the Wealth of New Data in Treatments for Neovascular Retinal Disease

(CME Track) Rapid Reviews in Retina™: Emerging Updates from Summer 2025—Addressing the Wealth of New Data in Treatments for Neovascular Retinal Disease

Mark R. Barakat, MD, FASRS; David Eichenbaum, MD, FASRS

(CME Track) Collaborating Across the Continuum™: Best Practices in Patient-Centric Team Management of XLRP

(CME Track) Collaborating Across the Continuum™: Best Practices in Patient-Centric Team Management of XLRP

Ramiro Maldonado, MD; Rebecca Nelson, MS, CGC; Robert A. Sisk, MD, FACS, FASRS

(CME Track) The Evolution of MacTel Management: Integrating Neuroprotective Therapies Into Clinical Practice

(CME Track) The Evolution of MacTel Management: Integrating Neuroprotective Therapies Into Clinical Practice

Dante Pieramici, MD, FASRS; Dean Eliott, MD; Robin A. Vora, MD; Charles C. Wykoff, MD, PhD, FASRS

(CME Track) A Forward Look at Anti-VEGF Therapies: A Paradigm Shift in Neovascular Retinal Disease Management

(CME Track) A Forward Look at Anti-VEGF Therapies: A Paradigm Shift in Neovascular Retinal Disease Management

David Almeida, MD, PhD, MBA; Margaret A. Chang, MD, MS; Arshad M. Khanani, MD, MA, FASRS; Jessica Randolph, MD

(CME Track) Community Collaborative Connections™: Optimizing the Collaborative Care of Neovascular Retinal Disease in a New Age of Treatment

(CME Track) Community Collaborative Connections™: Optimizing the Collaborative Care of Neovascular Retinal Disease in a New Age of Treatment

Dilsher Dhoot, MD, FASRS; Jordana G. Fein, MD, MS; Deep Parikh, MD; Xiao-Yi (Ellie) Zhou, MD

Medical Crossfire®: Maximizing Durability Across Retinal Disease — What 3 Years of Evidence Means for Your Practice

Medical Crossfire®: Maximizing Durability Across Retinal Disease — What 3 Years of Evidence Means for Your Practice

Judy E. Kim, MD, FARVO, FASRS; Anat Loewenstein, MD, MHA; Deepak Sambhara, MD, FASRS

AREDS3 and Beyond: The Scientific Basis for B Vitamin Nutritional Supplementation in AMD

In-Person + Virtual Event

AREDS3 and Beyond: The Scientific Basis for B Vitamin Nutritional Supplementation in AMD

September 13, 2026

EyeCon 2026

EyeCon 2026

September 26, 2026

(CME Track) Beyond the Collarette: Empowering Patients in the Management of Demodex Blepharitis

(CME Track) Beyond the Collarette: Empowering Patients in the Management of Demodex Blepharitis

Stephen C. Pflugfelder, MD; Cecelia Koetting, OD, FAAO, DipABO

(COPE Track) Beyond the Collarette: Empowering Patients in the Management of Demodex Blepharitis

(COPE Track) Beyond the Collarette: Empowering Patients in the Management of Demodex Blepharitis

Stephen C. Pflugfelder, MD; Cecelia Koetting, OD, FAAO, DipABO

Navigating Ocular Toxicities: A Multidisciplinary Roadmap for Managing Adverse Events in Targeted Cancer Therapy

Navigating Ocular Toxicities: A Multidisciplinary Roadmap for Managing Adverse Events in Targeted Cancer Therapy

Basil Williams, MD; Maura Di Nicola, MD

Bridging Regional Challenges in Retinal Disease Management: Applying Advanced Anti-VEGF Therapy in Community Practice - California

Bridging Regional Challenges in Retinal Disease Management: Applying Advanced Anti-VEGF Therapy in Community Practice - California

Dilsher S. Dhoot, MD, FASRS

When Mites Meet Their Match: Empowering Patients With Targeted Treatment for 𝘋𝘦𝘮𝘰𝘥𝘦𝘹 Blepharitis

When Mites Meet Their Match: Empowering Patients With Targeted Treatment for 𝘋𝘦𝘮𝘰𝘥𝘦𝘹 Blepharitis

Mile Brujic, OD, FAAO; Pierce Kenworthy, OD, FAAO; Blair Lonsberry, MS, OD, MEd, FAAO

Bridging Regional Challenges in Retinal Disease Management: Applying Advanced Anti-VEGF Therapy in Community Practice - Florida

Bridging Regional Challenges in Retinal Disease Management: Applying Advanced Anti-VEGF Therapy in Community Practice - Florida

Carl J. Danzig, MD, FASRS

The Presbyopia-Correcting and Toric IOL Playbook: Game-Changing Surgical Strategies to Enhance Patient Outcomes

The Presbyopia-Correcting and Toric IOL Playbook: Game-Changing Surgical Strategies to Enhance Patient Outcomes

Uday Devgan, MD, FACS, FRCS

(CME) The Truth About Presbyopia Drops: Evidence-Based Cases and Myth-Busting Insights

(CME) The Truth About Presbyopia Drops: Evidence-Based Cases and Myth-Busting Insights

Damon Dierker, OD FAAO; Maria Pribis, OD

Trending on Optometry Times - Clinical News & Expert Optometrist Insights

Bausch + Lomb advances 2 first-in-class eye health therapies

FDA expands TearCare indication to improve meibomian gland function

Study: Meta-analysis finds teacher-led vision screening highly specific for refractive error

Instilling safe contact lens wearing practices in patients

Not all myopia is the same: Noha Ekdawi, MD, FAAP, on individualized management